FIEP Has Supported RTU MIREA in Developing an Educational Program for Biopharmaceutical Companies

19 May 2021

The RUSNANO’s Fund for Infrastructure and Educational Programs (FIEP) (part of the VEB.RF Group) has supported the development of a professional retraining course on “Development, conduct, and management of biosynthesis and chromatography processes in modern biopharmaceutical production”. The program has been commissioned by the Generium biopharmaceutical company, which develops and manufactures medicines for the treatment of orphan diseases and has recently become one of the largest production sites for the new Gam-Covid-Vac (Sputnik V) coronavirus vaccine.

The new program is being prepared by MIREA—Russian Technological University. The 250-hour course will be used to improve the skills of technologists involved in the development, maintenance, and management of process technology in biopharmaceutical companies. In particular, specialists will be trained in modern methods of culturing and chromatographic purification of proteins in drug production.

The customer of the program is the Generium research and production company, approved by the Russian Ministry of Health as the manufacturer of the GAM-COVID-Vac (Sputnik V), the COVID-19 vaccine. The company’s production facilities and R&D park are located in the Vladimir Region, where state-of-the-art technological approaches and advanced equipment have been introduced.

“Fruitful cooperation with the Generium biopharmaceutical products manufacturer, with the support of the RUSNANO’s Fund for Infrastructure and Educational Programs, has made it possible to create not only a state-of-the-art training program based on the Master’s Degree program in the RTU MIREA but also to develop an advanced training program for production technologists. This program will also be a good basis for training technologists at the RTU MIREA, given the rapid development of the biopharmaceutical industry,” says Stanislav Kudzh, Rector of MIREA—Russian Technological University.

Workers who will be involved in the production need to expand their existing competencies. Additional knowledge and skills will not interfere with the employees of the company’s R&D park who have the potential to develop any biotechnology-based drug, from the creation of a molecule through to commercial production, and have expertise in the development of drugs for inherited diseases and asthma.

“The pandemic situation has proved once again that the winners in pharmaceuticals were the companies that could quickly restructure their production and adopt new high-tech products whose time-to-market was a year away. However, this required qualified personnel who could look one step ahead to the current needs and opportunities” said Stanislav Nisimov, Director of the Department of Education Programs and Professional Skills at FIEP.

“The support of the retraining program by the RUSNANO’s Fund for Infrastructure and Educational Programs will allow us to qualitatively improve and increase the competencies of our employees, as biotechnology is rapidly developing, and it is important for us to always meet the modern requirements of the industry,” emphasized Professor Ravil Khamitov, General Director of MBC Generium LLC.

The educational program will be offered to other companies in the industry, and the developers are confident that there will be a high demand for it. In Russia, the research and production complex of the biopharmaceutical industry, one of the most knowledge-intensive and high-tech sectors of the economy, is undergoing active technological modernization.

A total of 28 programs in the field of advanced medicine and pharmacology for Russian companies have been prepared with the participation of the Fund. They have already been used to train more than 20,500 production specialists, doctors, students, and residents. These include programs in nuclear medicine, computational biology, the production of nanopreparations, exorehabilitation, and modern methods of diagnosis and therapy for various diseases, including cancer.


The Fund for Infrastructure and Educational Programs was established in 2010 in accordance with Federal Law No. 211-FZ “On reorganization of the Russian Corporation of Nanotechnologies.” The Fund aims to develop the innovative infrastructure in the sphere of nanotechnology and implement the educational and infrastructure programs already started by RUSNANO.

The supreme collegial management body of the Fund is the Supervisory Board. Under the Fund’s Charter, the competence of the Supervisory Council, in particular, includes the issues of determining the priority directions of the Fund’s activity, as well as its strategy and budget. The Chairman of the Fund’s Executive Board, the collegial management body, is the Chairman of the Board of Management Company RUSNANO LLC Sergey Kulikov.